Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless”.

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID-19, the debilitating ...

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

El ensayo clínico, que busca reclutar a 1000 pacientes con COVID persistente en todo el país, explorará cómo la autoadministración de tirzepatida, el agonista del GLP-1 de Eli Lilly comercializado ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom.

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...